DocMorris
researchedfull dossierA pharmacy that owns its own prescriber, which is the exact structure §11 ApoG exists to prevent, and it lost on that point in April 2026.
DocMorris AG (Frauenfeld, Switzerland, listed on SIX as DOCM, ISIN CH0042615283), renamed from Zur Rose Group AG on 4 May 2023. Dispenses into Germany from Heerlen, Netherlands. Owns TeleClinic outright.
Model
A Dutch-dispensing mail-order pharmacy under a Swiss-listed parent, plus TeleClinic, a wholly owned telemedicine provider that prescribes GLP-1s by video after a self-reported questionnaire. Sells prescription medicines at the German Apothekenverkaufspreis. Has no Swiss pharmacy at all since the 2023 disposal.
Ownership
Listed on SIX. A separate company from Redcare Pharmacy, which is a rival. MediService AG was never a Zur Rose asset and is now 51 per cent owned by Redcare, not DocMorris.
Pricing
Mounjaro 2.5 mg self-pay at €206.80, the AVP to the cent, with a €5.00 Rezept-Bonus and free shipping, verified live on the product page. Its tiered E-Rezept-Rabatt of €2.50 to €20 is Kassenrezept-only and unavailable to a weight-loss patient. TeleClinic charges €38.87 for the consultation, computed under the GOÄ rather than as a platform fee.
Funding
Listed. Has had a difficult financial period. Sold its entire Swiss business to Galenica and Medbase in 2023, the same day it renamed itself.
Scale
TeleClinic claims over 20,000 obesity treatments, 4 million treatments in total, 3.2 million app downloads, and transmits prescriptions free to more than 13,000 of roughly 15,000 German pharmacies. 117 indexed GLP-1 URLs on the German property.
Regulatory history
On 29 April 2026 in LG Köln 84 O 156/22, the Apothekerkammer Nordrhein won a holding that steering patients from DocMorris to its wholly owned TeleClinic breaches §11 ApoG because DocMorris profits from the resulting turnover, and separately that questionnaire-based prescribing without physical examination meets no recognised professional standard. Not final. This corrects our earlier record, which dated the ruling to Munich in 2024.
In 2026
The group holds no German §11a ApoG permit and cannot, so its entire German business rests on the Netherlands remaining on the Länderliste. The annual report contains zero occurrences of "Länderliste", "§ 73" or "Versandhandelserlaubnis", so that dependency is undisclosed as a risk while the Freie Apothekerschaft has a Verpflichtungsklage pending at VG Köln.
Markets
Germany, Netherlands, Austria, France, Spain, Italy.
Covered in this atlas: Austria, Germany, Spain, France, Italy, Netherlands.
What this dossier changes
DocMorris is a pharmacy that owns its own prescriber outright, which is the exact structure section 11 ApoG exists to prevent, and on 29 April 2026 it lost on that point. The same judgment held that questionnaire-based prescribing without physical examination meets no recognised professional standard, which is a description of every GLP-1 funnel in this atlas.
Corporate
Every operating entity, and the chain from the local company up to the ultimate parent.
| Entity | Jurisdiction | Number | Role |
|---|---|---|---|
| DocMorris AG | Switzerland | ISIN CH0042615283, SIX: DOCM | The listed parent, Frauenfeld. Renamed from Zur Rose Group AG by AGM resolution on 4 May 2023, the same day the Swiss disposal closed. The ISIN was unchanged through the rename. The DocMorris brand itself had been acquired eleven years earlier, in October 2012. |
| DocMorris N.V. and the Heerlen pharmacy operation | Netherlands | n/a | Where the German business actually dispenses from. The seller on the German product records is recorded with country code NL. |
| TeleClinic GmbH | Germany | n/a | Wholly owned. A telemedicine provider that prescribes GLP-1s by video consultation after a self-reported questionnaire, charges 38,87 EUR computed under the GOÄ, and transmits prescriptions free to more than 13,000 of roughly 15,000 German pharmacies. A pharmacy group owning a prescriber outright is the structure section 11 ApoG addresses. |
| DocMorris Services B.V. | Netherlands | n/a | Runs the Marktplatz. Not a pharmacy, and the marketplace covers non-prescription products only. This is why a DTC brand structurally cannot have DocMorris dispense prescriptions on its behalf. |
| MediService AG and Zur Rose Suisse AG | Switzerland | n/a | Neither belongs to DocMorris. MediService was never a Zur Rose asset at all: Galenica bought it in 2007 and sold 51 per cent to SA Europe B.V., which is Redcare, in 2023. Zur Rose Suisse went to Medbase and Migros. DocMorris has no Swiss pharmacy. |
DocMorris AG (Switzerland, SIX: DOCM, ex Zur Rose Group AG since 4 May 2023) | +-- Dutch pharmacy operation, Heerlen dispenses into Germany +-- TeleClinic GmbH (Germany) WHOLLY OWNED PRESCRIBER +-- DocMorris Services B.V. (NL) Marktplatz, non-pharmacy, non-Rx The loop LG Köln attacked on 29 April 2026: docmorris.de obesity hub --[campaign tag 1688-docmorris-obesity-hub]--> TeleClinic --[38,87 EUR, video consultation, Privatrezept]--> patient chooses a pharmacy --> DocMorris is the largest and most advertised option --> DocMorris takes the dispensing margin The court's reasoning: "DocMorris profitiere von dem Umsatz". The group profits either way, whatever the pharmacy-selection screen does. Not in this group, contrary to a common error: MediService AG -> 51% Redcare, acquired from Galenica Zur Rose Suisse -> Medbase / Migros
Licences
Who actually holds the pharmacy registration, the clinical registration and the prescribers. This is the block that most often contradicts a company's own description of itself.
The permit requires a German Apothekenbetriebserlaubnis, which a Dutch operation cannot have. Shipping runs under section 73(1) sentence 1 no. 1a AMG.
The annual report contains zero occurrences of "Länderliste", zero of "section 73" and zero of "Versandhandelserlaubnis". The single legal predicate of the whole German business is not named as a risk anywhere, while the Freie Apothekerschaft has a Verpflichtungsklage pending at VG Köln. Its urgent application failed at OVG NRW on 9 April 2026 on standing, not on the merits.
The Swiss business was sold to Galenica and Medbase on 4 May 2023. A Swiss-domiciled, Swiss-listed company with no Swiss pharmacy.
The single most consequential regulatory holding in this atlas for anyone contemplating owning both the prescriber and the dispenser.
Money
Listed, and financially strained
Multi-year revenue by segment and market, the prescription versus over-the-counter split, electronic prescription revenue, active customers, average basket, adjusted EBITDA, net debt and the refinancing history are all published, which makes this the second company in the atlas whose position can be read rather than inferred. The group has had a difficult few years, and the German electronic prescription rollout is the entire strategic story.
Zero GLP-1 revenue disclosure anywhere
Exactly as with Redcare. The strategy is visible only in a June 2025 free obesity adherence programme bolted onto prescription reminder and repeat prescription services, which reads as retention rather than acquisition. Two listed pharmacies with a combined 274 indexed GLP-1 URLs discuss the category in no investor document at all.
The margin is the pharmacy margin, and it is being competed below par
The self-pay price for Mounjaro 2.5 mg is 206,80 EUR, the Apothekenverkaufspreis to the cent, with a 5,00 EUR Rezept-Bonus badge and free shipping. Verified live on the product page on 25 August 2026, which corrects an earlier figure of a 2,50 EUR bonus. Its tiered E-Rezept-Rabatt of 2,50 to 20 EUR is contractually statutory-prescription-only and therefore unavailable to a weight-loss patient, who is always on a Privatrezept because GLP-1s for obesity are excluded from statutory reimbursement under SGB V section 34.
Markets
One card per country, live or not. A competitor's absence from a market is as informative as their presence.
- Entity
- Dutch pharmacy operation, Heerlen
- Pharmacy
- Own
- Prescribers
- TeleClinic, wholly owned
The main market and the one in litigation. 117 indexed GLP-1 URLs.
- Entity
- DocMorris group
- Pharmacy
- Own
- Prescribers
- None
- Entity
- DocMorris group
- Pharmacy
- Own
- Prescribers
- None
- Entity
- DocMorris group
- Pharmacy
- Own
- Prescribers
- None
- Entity
- DocMorris group
- Pharmacy
- Own
- Prescribers
- None
- Entity
- DocMorris group
- Pharmacy
- Own
- Prescribers
- None
- Entity
- None
- Pharmacy
- None
- Prescribers
- None
Swiss-domiciled and Swiss-listed, with no Swiss pharmacy since the 2023 disposal to Galenica and Medbase. Our atlas previously attributed MediService to this group; that was wrong, and MediService is 51 per cent Redcare.
Positioning
The actual words. Paraphrase loses the evidence.
Mit welchem in Deutschland zugelassenen Medikament wollen Sie Ihre Adipositas behandeln lassen? Mounjaro / Wegovy / Saxenda / Keine Präferenz
With which medicine authorised in Germany do you want your obesity treated? Mounjaro / Wegovy / Saxenda / No preference
A patient-facing, brand-named product picker inside the intake of a telemedicine service wholly owned by a pharmacy, with the disclaimer that the doctor decides sitting directly beneath it. There is a second brand-named question later in the same questionnaire. This is the closest thing to advertising prescription-only brands to the public that either listed group operates, and it is precisely the pattern the April 2026 judgment attacks.
Beratung, Rezept & Krankschreibung direkt online anfragen. In wenigen Klicks von Zuhause per Videosprechstunde mit Ärzten online sprechen. Mit Kostenübernahme Ihres Online-Arztbesuchs durch alle Krankenkassen. [Zur TeleClinic Videosprechstunde]
Request advice, prescription and sick note directly online. Speak to doctors online by video consultation from home in a few clicks. With the cost of your online doctor visit covered by all health insurers. [To the TeleClinic video consultation]
TeleClinic is wholly owned by DocMorris. This panel sits directly beneath the add-to-basket button on a prescription-only GLP-1. It is the first limb of the LG Köln holding of 29 April 2026, that steering from DocMorris to TeleClinic breaches section 11 ApoG because the group profits from the turnover, rendered in a single screen.
In der App können alle im Versandhandelsregister eingetragenen Versandapotheken über den Button „Übersicht aller Versandapotheken" gefunden werden. Die freie Apothekenwahl wird stets gewährleistet.
In the app all mail-order pharmacies entered in the mail-order register can be found via the "Overview of all mail-order pharmacies" button. Free choice of pharmacy is always guaranteed.
And the client bundle backs it up. See the gating section: this is the limb DocMorris actually wins on.
Die Behandlung von Adipositas in Deutschland ist eine Selbstzahlerleistung. Die Behandlungskosten belaufen sich auf 38,87 €. Über 40 gesetzliche Krankenkassen mit Partnervertrag zu TeleClinic übernehmen die Kosten für die Videosprechstunde.
Treatment of obesity in Germany is a self-pay service. The treatment costs amount to 38.87 EUR. Over 40 statutory health insurers with a partner contract with TeleClinic cover the costs of the video consultation.
The 38,87 EUR is stated as computed under the GOÄ, the German medical fee schedule, not as a platform fee. That is a meaningfully better legal posture than Zava’s 33,99 EUR or DoktorABC’s 49 EUR, both of which are simply prices the company chose. And a consultation many patients get free through their insurer is a competitive fact no DTC brand can match.
Ärztinnen und Ärzte können je nach individueller ärztlicher Bewertung des Einzelfalls u.a. eine sog. „Abnehmspritze" verordnen.
Doctors can, depending on individual medical assessment of the case, prescribe among other things a so-called "slimming injection".
The quotation marks around Abnehmspritze are doing careful work. The public page uses the generic term while the intake questionnaire behind it lists three brand names as menu options.
Während viele telemedizinische Behandlungen auf eine akute Fragestellung fokussiert sind, steht bei Adipositas für mich die strukturierte, langfristige und medizinisch fundierte Begleitung einer chronischen Erkrankung im Mittelpunkt.
While many telemedicine treatments focus on an acute question, for me obesity is about structured, long-term, medically grounded support of a chronic illness.
Naming and gating
Prescription-only medicines cannot be advertised to the public anywhere in Europe. So how does this competitor refer to the drug, and what stands between a visitor and the brand name?
The pharmacy-selection question, answered from the code, and DocMorris wins this limb
The TeleClinic patient bundle is 3.6 megabytes and was read in full. It contains a partner registry of eleven partners. The DocMorris entry has exactly three properties and no partner pharmacy linkout at all, while ADAC has roughly thirty properties including a linkout pointing at IhreApotheken, and AOK Bayern has one pointing at an AOK endpoint. There is no DocMorris default constant, no DocMorris pharmacy object, and the capitalised string "DocMorris" appears zero times in the entire bundle. The redemption flow is a local pharmacy map plus an overview of every mail-order pharmacy in the Versandhandelsregister, plus E-Rezept and Gematik app linkouts, with the instruction to go to any pharmacy you like. No discount, speed advantage or bonus is available only on the DocMorris path. The steering mechanism exists in the codebase, other partners use it, and the one partner that owns TeleClinic conspicuously does not.
But the first limb stands untouched, and it is the one that matters
The LG Köln holding is that steering from DocMorris to TeleClinic breaches section 11 ApoG because DocMorris profits from the resulting turnover. Nothing in the pharmacy-selection screen weakens that. The economic loop closes at group level: DocMorris drives obesity traffic into TeleClinic under a campaign tag that literally reads 1688-docmorris-obesity-hub, TeleClinic charges the patient 38,87 EUR and issues a private prescription, and DocMorris is then the largest and most advertised mail-order option in the list the patient is shown. Do not read the free-choice finding as DocMorris winning.
And the second holding stands unqualified
The court also held, on expert evidence and rejecting a no-harm defence, that questionnaire-based prescribing without physical examination meets no recognised professional standard. TeleClinic’s obesity route is better than most, because the questionnaire feeds a video consultation rather than replacing it. But step three of that questionnaire is height and weight, self-reported, with file upload set to not required. There is no measurement, no bloods and no examination. That is the gap the court identified, and it applies with far more force to every pure asynchronous funnel in this atlas.
Naming: open, indexed, and with the weakest compliance markers of the two pharmacies
117 indexed GLP-1 URLs, all pages emitting index,follow with a self-referential canonical, no login, no age gate, no prescription-upload interstitial. Where Shop Apotheke runs a proper per-product Pflichtangaben block with a linked leaflet, DocMorris runs one global footer sentence sitewide and zero occurrences of Pflichtangaben. Neither cites the Heilmittelwerbegesetz once.
The most exposed single item on the estate
DocMorris runs an email waitlist for the Wegovy tablet, a medicine not yet authorised. Advertising an unauthorised medicinal product engages section 3a HWG, which is a different and stricter prohibition from the section 10 public-advertising rule everyone else in this atlas is arguing about.
Funnel
Every screen from landing to checkout. Three gates are marked: where price is first revealed, where payment is taken, and where the clinical assessment sits. The order of those three is the commercial model.
- docmorris.de obesity hub
captures: nothing
Campaign tag 1688-docmorris-obesity-hub. The steering the court found unlawful.
- Hand off to TeleClinic
captures: nothing
- Questionnaire step 1, previous weight-loss attempts
captures: history, including a brand-named question about which medicines were used
- Questionnaire step 2, relevant preconditions
captures: prediabetes, type 2 diabetes, hypertension, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea
- Questionnaire step 3
captures: height and weight, self-reported, file upload not required
BMI is computed from self-declared numbers. No measurement, no bloods, no examination. This is the step the court identified.
- Questionnaire step 4, the brand picker
Mit welchem in Deutschland zugelassenen Medikament wollen Sie Ihre Adipositas behandeln lassen? Mounjaro / Wegovy / Saxenda / Keine Präferenz
captures: brand preference
- Questionnaire step 5, eating patterns and exercise
- Exit gatesclinical gate
Genuine ones: normal weight, not eligible, and a pregnancy gate specifically triggered when the patient has selected Mounjaro, Wegovy or Saxenda.
- Video consultation with a doctor, 38,87 EURpayment gate
A real video call, not pure asynchronous review, which is a materially better posture than Zava or DoktorABC. Priced under the GOÄ. Over 40 statutory insurers cover it.
- Private prescription issued to the app
- Patient chooses any pharmacy
Local map plus every mail-order pharmacy in the register, plus E-Rezept and Gematik linkouts. No DocMorris preselection, no DocMorris-only benefit. The pharmacy identifies itself with its IK-Nummer to download a QES-signed prescription, which is then blocked at every other pharmacy.
Pricing
Germany, Mounjaro 2.5 mg, the complete ladder across every route researched
| Route | Medicine | Consultation | Total |
|---|---|---|---|
| DocMorris self-pay (Privatrezept) | 206,80 € | n/a | 206,80 €, with a 5,00 € Rezept-Bonus |
| Shop Apotheke self-pay | 206,80 € | n/a | 206,80 € |
| DocMorris via TeleClinic | 206,80 € | 38,87 €, often covered by the insurer | 206,80 to 245,67 € |
| Shop Apotheke via the Zava referral | 206,80 € | 9 to 29 € | 215,80 to 235,80 € |
| Zava direct | 206,80 € | 33,99 € | 240,79 € |
| DoktorABC | 235,80 € | 49,00 € | 284,80 € |
Live on 25 August 2026 both listed pharmacies show 206,80 EUR with a 5,00 EUR prescription bonus badge, so the headline spread between them is zero and the bonuses differ only in what they can be spent on. Every euro above 206,80 in this table is a fee for arranging a prescription, and TeleClinic is the only one of those fees computed under a statutory schedule rather than chosen, and the only one over forty statutory insurers will pay.
The TeleClinic fee schedule, and what it tells you about pricing legitimacy
| Item | Price |
|---|---|
| Adipositas consultation, Monday to Friday | from 37,54 € |
| Base doctor consultation, including letter, prescription and sick note | 38,87 € |
| Surcharge 06:00 to 08:00 and 20:00 to 22:00 | 10,49 € |
| Surcharge 22:00 to 06:00 | 18,65 € |
| Saturday | 6,41 € |
| Sunday and public holidays | 12,82 € |
| For comparison, contraceptive prescription by questionnaire | from 9,98 € |
Prices are stated as computed under the GOÄ. That is why the obesity consultation costs four times a contraceptive prescription: it is a video consultation rather than a questionnaire review. An entrant that prices under a statutory schedule has an answer to the question of why the fee is what it is.
Surface
Domains from certificate transparency, not guesswork. Staged markets and internal tooling show up here first.
The BGH has already written the term sheet for a pharmacy partnership
BGH I ZR 46/24, the Partnervertrag decision of 20 February 2025, held that a flat platform fee of 399 EUR per month is lawful, while per-prescription or revenue-share arrangements constitute unlawful Rezeptmakeln under section 11(1a) ApoG. A 10 per cent over-the-counter transaction fee was remitted for a materiality test under section 8 ApoG. So the shape of a lawful German pharmacy partnership is now judicially defined: pay a flat fee, never a share.
But you still cannot have DocMorris dispense your prescriptions
The Marktplatz is run by DocMorris Services B.V., which is not a pharmacy, and it covers non-prescription products only. The marketplace is closed, no rates are published, and there is no precedent of any telemedicine or DTC weight-loss partnership. Combined with the Redcare finding, the conclusion for an entrant is firm: neither listed pharmacy will dispense prescription medicines for a third-party brand, and the only prescription telemedicine relationship either has is Redcare’s with Zava, which is unpublished and in litigation.
TeleClinic is quietly building the pharmacy-side business instead
Prescription transmission is free to more than 13,000 of roughly 15,000 German pharmacies, and since 1 July 2026 TeleClinic sells those pharmacies assisted telemedicine at 30,00 EUR per consultation under section 129(5h) SGB V. There is also a hidden employer-benefit obesity programme in the treatment registry, marked as not shown in the public treatment list. The group is monetising the channel rather than the patient.
The steering is on the product page itself, not just the category hub
Captured live on 25 August 2026 and stronger than the campaign-tag evidence. The Mounjaro 2,5 mg product page carries, inside the buy box directly under the add-to-basket button, a panel headed "Beratung, Rezept und Krankschreibung direkt online anfragen" with a primary button reading "Zur TeleClinic Videosprechstunde" and a secondary link to find a local doctor. So a patient looking at a prescription-only GLP-1 on DocMorris is offered a route to a prescriber DocMorris owns, on the product page, one click from the basket. That is the exact analogue of Shop Apotheke’s Zava interstitial, and it is the first limb of the LG Köln holding in a single screenshot.
Reputation
Read the one-star reviews properly. They describe the operational model from the outside.
Not comparable to the DTC brands, and worse than its listed rival
Trustpilot could not be reached from this environment, so Trusted Shops was substituted, giving a bottom-band rate of 3.33 per cent for DocMorris against 1.57 per cent for Shop Apotheke. As with Redcare, a mail-order pharmacy’s reviews measure delivery and service across a whole catalogue and say nothing about a weight-loss programme. TeleClinic separately claims an average of 4.9 stars, over 20,000 obesity treatments, over 4 million treatments in total, over 3.2 million app downloads, roughly four minutes of waiting time, and obesity requests picked up within four hours on average.
Visual evidence
Captured live from the public site. Each carries its URL and the date it was taken.
The section 11 ApoG artefact, live on the product page. Mounjaro 2,5 mg at 206,80 EUR, the German list price to the cent, sold by DocMorris Apotheke, sofort verfügbar, with a 5,00 EUR Rezept-Bonus. And directly beneath the buy button, in the same box: "Beratung, Rezept und Krankschreibung direkt online anfragen", with a button reading "Zur TeleClinic Videosprechstunde". TeleClinic is wholly owned by DocMorris. This is the steering LG Köln held unlawful on 29 April 2026, sitting on the product page of a prescription-only GLP-1.
The same page with the Kassenrezept tab selected: a 10,00 EUR statutory copayment discounted by a 10,00 EUR Zuzahlungsrabatt to nothing, against UVP/AVP 206,80 EUR. A weight-loss patient never sees this tab, because GLP-1s for obesity are excluded from statutory reimbursement under SGB V section 34 and every such prescription is a Privatrezept.
TeleClinic, wholly owned by DocMorris. Übergewicht und Adipositas nachhaltig behandeln. Behind this page sits a video consultation at 38,87 EUR priced under the GOÄ, and an intake questionnaire whose step four asks the patient to choose between Mounjaro, Wegovy and Saxenda. On 29 April 2026 LG Köln held that steering patients here from DocMorris breaches section 11 ApoG, and that questionnaire-based prescribing without physical examination meets no recognised professional standard.
Exposure
Rulings, investigations and open matters, dated. Then: what is still live on the site that the ruling was about.
First, steering patients from DocMorris to its wholly owned TeleClinic breaches section 11 ApoG, in the court’s words because DocMorris profits from the turnover. Second, and more broadly applicable, questionnaire-based prescribing without physical examination meets no recognised professional standard. That second holding was reached on expert evidence and the no-harm defence was rejected. It transfers directly to every GLP-1 funnel in this atlas, and with far more force to the pure asynchronous ones, since TeleClinic at least runs a video consultation.
LG Frankfurt am Main 2-06 O 150/25 of 28 May 2025 held that a platform operator is not even an addressee of section 11(1). OLG Frankfurt 6 W 108/25 of 14 August 2025 is reported the other way. The full text of the second could not be retrieved. Recorded as an unresolved contradiction rather than resolved, because it is genuinely unresolved and an entrant should know that the law here is unsettled rather than merely strict. Note also that section 11(1) sentence 3 expressly extends to EU and EEA pharmacies supplying Germany, so the idea that the prohibition does not reach Dutch senders has no support in the statute and no BGH authority was found for it.
A flat platform fee of 399 EUR per month was accepted. A volume-blind fee speaks against Rezeptmakeln unless it is a concealed success commission because the fee is excessive against the service provided. Revenue share was not held unlawful outright. A 10 per cent over-the-counter transaction fee was remitted for a materiality test under section 8 ApoG. This is the most useful piece of German case law in the whole atlas for anyone designing a commercial structure.
DocMorris holds no German section 11a ApoG permit and cannot. Its entire German business rests on section 73(1) sentence 1 no. 1a AMG and therefore on the Netherlands remaining listed. The annual report names none of that as a risk: zero occurrences of Länderliste, section 73 or Versandhandelserlaubnis. Redcare’s reports have the same silence. Two listed companies whose German revenue depends on one political line item, neither of which discusses it.
DocMorris runs a Wegovy tablet waitlist. Section 3a HWG prohibits advertising a medicinal product that is not authorised, which is a separate and stricter prohibition from the section 10 public-advertising rule the rest of this atlas turns on. It is the most exposed single item on the DocMorris estate and it is entirely self-inflicted.
Zur Rose Group AG became DocMorris AG by AGM resolution on 4 May 2023, the same day the Swiss disposal closed, with the ISIN unchanged. Recorded because the confusion between DocMorris, Zur Rose, Redcare and MediService is widespread and our own atlas carried it. A search engine surfaced a Lenz und Staehelin deal page as if it were the recent transaction; it is from 2007 and would have inverted the ownership history entirely.
Read-across
What a new entrant should copy, and what it should avoid.
Copy this
- Price the consultation under a statutory fee schedule. TeleClinic charges 38,87 EUR computed under the GOÄ, publishes the full ladder including night and weekend surcharges, and gets over 40 statutory insurers to pay it. Zava’s 33,99 EUR and DoktorABC’s 49 EUR are simply prices they chose, which is a weaker position both commercially and legally.
- Run a video consultation, not an asynchronous review. The April 2026 judgment held questionnaire-only prescribing meets no recognised professional standard, on expert evidence, with the no-harm defence rejected. A video call is the single cheapest piece of insurance against that holding.
- Guarantee free choice of pharmacy and build it properly. TeleClinic offers a local map plus every mail-order pharmacy in the register plus E-Rezept and Gematik linkouts, states on the record that free choice is always guaranteed, and, verifiably in its own code, gives its owner no preselection and no exclusive benefit. That is a defensible build, and it is what half the section 11 ApoG argument turns on.
- Charge pharmacies nothing for prescription transmission, then sell them something else. TeleClinic transmits free to 13,000 of 15,000 German pharmacies and since July 2026 sells them assisted telemedicine at 30,00 EUR a consultation under section 129(5h) SGB V. That is a channel business built on top of a giveaway, and it is a better moat than a consumer funnel.
- If you need a German pharmacy partner, use the structure the BGH blessed: a flat monthly platform fee. I ZR 46/24 held 399 EUR a month lawful and per-prescription or revenue-share unlawful. The term sheet is already written.
Avoid this
- Do not own both the prescriber and the dispenser in Germany. That is the structure section 11 ApoG exists to prevent, DocMorris lost on it in April 2026, and the court’s reasoning was simply that the group profits from the turnover. No amount of free-choice engineering at the redemption step answers that.
- Do not put brand names in the intake questionnaire. "With which medicine authorised in Germany do you want your obesity treated: Mounjaro, Wegovy, Saxenda" is a brand picker presented to the public by a pharmacy-owned prescriber, and the disclaimer underneath that the doctor decides does not obviously cure it.
- Do not run a waitlist for an unauthorised medicine. Section 3a HWG is stricter than the section 10 rule everyone argues about, and a Wegovy tablet email capture is about as clean a fact pattern as a complainant could ask for.
- Do not rely on self-reported height and weight as the only body data. It is step three of the TeleClinic obesity questionnaire with file upload not required, it is what the GPhC criticised at Zava UK, and it is what the German court identified. Yazen’s connected scale and 3D modelling is the answer, and it is not expensive.
- Do not assume the platform-operator defence works. LG Frankfurt held a platform operator is not even an addressee of section 11(1); OLG Frankfurt is reported the other way; and section 11(1) sentence 3 expressly extends to EU and EEA pharmacies supplying Germany. Build as though you are caught.
- Do not omit the Länderliste from your risk register just because both listed incumbents do. Neither annual report mentions it once, and it is the one condition on which the entire German cross-border channel depends.
Open on this company
- Is the LG Köln judgment of 29 April 2026 under appeal at OLG Köln, and has it been stayed? It is not final and the answer changes the risk materially. Closable through the LG Köln press office or the Apothekerkammer Nordrhein legal department.
- What does OLG Frankfurt 6 W 108/25 of 14 August 2025 actually hold? The full text could not be retrieved and it is the counterweight to LG Frankfurt 2-06 O 150/25 on whether a platform operator is caught by section 11(1) at all.
- Does DocMorris disclose the TeleClinic litigation in its annual report risk factors, and how does it quantify it? Not established.
- What is DocMorris’s consent-management posture? Its platform sets google_consent_mode to false, which needs one browser session to confirm or clear. The domain was refused by the extension.
- Is the 5,00 EUR Rezept-Bonus on a Privatrezept cash, store credit, or restricted like Shop Apotheke’s cosmetics-only credit? The badge is on the page but the terms behind it were not read. It is the only remaining difference between the two listed pharmacies on price.
- What are the Marktplatz commercial terms? It is described as closed with no published rates, against Redcare which publishes 16 per cent commission, a 499 EUR setup and 39 EUR per country per month.